preludetx
An Executive Director of Computational Chemistry leading computational drug discovery in a biotech environment. The role focuses on driving novel small molecule design using AI/ML and structure-based drug design, while also implementing AI tools across discovery programs.
Headquarters
Wilmington, Delaware, United States
Company Size
51-200 employees
Founded
2016
Prelude Therapeutics is a leading precision oncology company developing innovative medicines for cancer patients with high unmet need. Its pipeline features highly selective KAT6A degraders, mutant-selective JAK2V617F JH2 inhibitors, and next-generation degrader antibody conjugates (DACs) with novel payloads — new approaches to clinically validated targets with transformative potential. Leveraging deep expertise in targeted protein degradation and precision small-molecule design, Prelude's mission is to extend the promise of precision medicine to every cancer patient in need.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for preludetx.
preludetx didn’t post a salary, so this is our estimate from similar listings.
Scientific Leader, Integrated Medicinal Chemistry, Computational Chemistry, Cheminformatics and DMPK
Relay Therapeutics
Computational Chemistry Lead
Astellas
Associate Director, Computational Chemistry
Takeda Pharmaceutical Company Limited
Principal Scientist (Computational Chemistry)
Exelixis
Senior Director, AIRx Computational Chemistry
Takeda Pharmaceutical Company Limited
Scientist, Computational Medicinal Chemistry
Monte Rosa Therapeutics, Inc